PHI-101 is an orally active, potent third-generation inhibitor of FLT3 that overcomes resistance to multiple drug-resistant mutations. It has potential for research in relapsed or refractory acute myeloid leukemia (AML).

EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts.

EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts.

PHI-101 is an orally active, potent third-generation inhibitor of FLT3 that overcomes resistance to multiple drug-resistant mutations. It has potential for research in relapsed or refractory acute myeloid leukemia (AML).

EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts.

EAPB02303 is a second-generation imiqualine that acts as a microtubule -disruptingagent and demonstrates anti-tumor effects and reduces tumor size in human melanoma xenografts.

(+)-JNJ-A07 is a highly potent inhibitor of Dengue virus (DENV) with an EC50 of 0.1 nM in the DENV-2 strain (16681) in Vero cells. It exhibits antiviral activity by preventing the formation of the viral replication complex through blocking the interaction between two viral proteins, NS3 and NS4B.

(+)-JNJ-A07 is a highly potent inhibitor of Dengue virus (DENV) with an EC50 of 0.1 nM in the DENV-2 strain (16681) in Vero cells. It exhibits antiviral activity by preventing the formation of the viral replication complex through blocking the interaction between two viral proteins, NS3 and NS4B.

(+)-JNJ-A07 is a highly potent inhibitor of Dengue virus (DENV) with an EC50 of 0.1 nM in the DENV-2 strain (16681) in Vero cells. It exhibits antiviral activity by preventing the formation of the viral replication complex through blocking the interaction between two viral proteins, NS3 and NS4B.

Talnetant (SB 223412) is a selective, competitive, brain-permeable NK3 receptor antagonist with a Ki of 1.4 nM in hNK-3-CHO cells. Talnetant is 100-fold more selective for hNK-3 relative to the hNK-2 receptor and has no affinity for hNK-1. Talnetant can be used in schizophrenia-related studies.